How should hypotension be managed after Tenecteplase (TNK) infusion?

Management of Hypotension Post-Tenecteplase (TNK)

Immediately discontinue any concomitant heparin or antiplatelet agents if hypotension is accompanied by serious bleeding, and provide appropriate supportive care including fluid resuscitation and vasopressor support as needed. 1

Initial Assessment and Immediate Actions

When hypotension develops after TNK administration, you must rapidly differentiate between three primary etiologies:

1. Bleeding-Related Hypotension

• Most critical to identify first - TNKase causes bleeding including intracranial hemorrhage and fatal bleeding 1
• Look for:
  • Signs of active bleeding (GI, retroperitoneal, intracranial)
  • Drop in hemoglobin/hematocrit
  • Bleeding from puncture sites
  • Neurological changes suggesting ICH

If bleeding is identified:

• Stop all anticoagulants and antiplatelet agents immediately 1
• Avoid intramuscular injections and minimize patient handling 1
• Apply direct pressure to any compressible bleeding sites for at least 30 minutes 1
• Transfuse blood products as appropriate
• Consider reversal agents (cryoprecipitate, tranexamic acid)

2. Reperfusion Arrhythmias

• Coronary thrombolysis commonly causes reperfusion arrhythmias including sinus bradycardia, accelerated idioventricular rhythm, ventricular premature depolarizations, and ventricular tachycardia 1
• Anti-arrhythmic therapy for bradycardia and ventricular irritability should be immediately available when TNKase is administered 1
• Manage with standard anti-arrhythmic measures 1
• Bradycardia may require atropine or temporary pacing
• Ventricular arrhythmias may require amiodarone or lidocaine

3. Cardiogenic Shock/Heart Failure

• TNKase plus PCI showed trends toward increased cardiogenic shock (6.3% vs 4.8% with PCI alone) 1
• Assess for:
  • Pulmonary edema
  • Elevated jugular venous pressure
  • New murmurs (acute mitral regurgitation, VSD)
  • Signs of right ventricular infarction

Management approach:

• Fluid challenge cautiously if no signs of volume overload
• Initiate vasopressor support (norepinephrine preferred)
• Consider inotropic support if cardiogenic shock confirmed
• Urgent echocardiography to assess ventricular function and mechanical complications

4. Hypersensitivity/Anaphylactic Reaction

• Urticarial/anaphylactic reactions including angioedema, laryngeal edema, rash, and urticaria have been reported 1
• Monitor patients during and for several hours after TNKase infusion 1
• If hypersensitivity suspected: initiate antihistamines and corticosteroids immediately 1
• Treat anaphylaxis with epinephrine, fluids, and airway management as needed

Critical Pitfalls to Avoid

NEVER flush TNKase lines with dextrose-containing solutions - this causes immediate crystallization and line occlusion, potentially denying the patient the fibrinolytic while compromising IV access 2. Always use 0.9% sodium chloride before and after TNKase administration 1.

Supportive Care Algorithm

1. Secure airway if needed (especially if hypersensitivity with laryngeal edema)
2. Establish adequate IV access with normal saline (not dextrose)
3. Fluid resuscitation with crystalloids if no pulmonary edema
4. Vasopressor initiation if hypotension persists despite fluids (norepinephrine first-line)
5. Continuous cardiac monitoring for arrhythmias
6. Serial hemoglobin checks to detect occult bleeding
7. Neurological assessments every 15 minutes initially to detect ICH

Blood Pressure Targets

While the FDA label lists severe uncontrolled hypertension (SBP >180 or DBP >110 mmHg) as a contraindication 1, there is no specific lower blood pressure threshold defined post-administration. Use clinical judgment based on end-organ perfusion (mental status, urine output, lactate levels).

The key is recognizing that hypotension post-TNK is a symptom requiring immediate investigation of the underlying cause rather than empiric treatment alone.